UCLA and City of Hope scientists use nanoparticles to shut down mechanism that drives cancer growth
When scientists develop cancer therapies, they target the features that make the disease deadly: tumor growth, metastasis, recurrence and drug resistance. In epithelial cancers — cancers of the breast, ovaries, prostate, skin and bladder, which begin in the organs’ lining — these processes are controlled by a genetic program called epithelial–mesenchymal transition. UCLA Jeffrey Zink Epithelial–mesenchymal transition is regulated by a protein called Twist, which means that Twist directly influences the development of cancer, its spread to other organs and its return after remission. In a major step toward developing a novel therapy that targets epithelial–mesenchymal transition, scientists from UCLA and City of Hope have become the first to inhibit the mechanism of Twist using nanoparticles to deliver a nucleic acid called small interfering RNA, or siRNA, into tumor cells. In mouse models, delivering siRNA into cancer cells inhibited the expression of Twist, which in turn reduced epithelial-mesenchymal transition and dramatically reduced the size of tumors. The study, which was published online in the journal Nanomedicine: Nanotechnology, Biology and Medicine, was led by Jeffrey Zink and Fuyu Tamanoi, both members of the California NanoSystems Institute and Jonsson Comprehensive Cancer Center at UCLA, and Carlotta Glackin of City of Hope Cancer Center. “We were truly surprised by the dramatic effect of delivering Twist siRNA,&r...
Aeyung Kim, Jin Yeul Ma
Gilead Sciences Inc. landed former Roche executive Daniel O'Day as its new CEO, and Genentech Inc.'s current CEO will take O'Day's role with Genentech's parent company in a game of musical chairs disclosed Sunday. The job shuffling has implications up and down the employment ranks of the Bay Area's two largest drug makers during critical times for both companies. Gilead (NASDAQ: GILD), based in Foster City, is set up for deeper moves into next-generation cancer drugs while South San Francisco's…
Two people developed cancer after organ donations from a woman who had the undetected disease.
This study explores the prevalence of clonal hematopoiesis related to radioactive iodine exposure and how it impacts overall survival in patients with thyroid cancer.Journal of Clinical Endocrinology &Metabolism
Training programs are needed to help employers improve communication with cancer survivors and facilitate workplace accommodations.Journal of the National Cancer Institute
Does long-term exposure to systemic immunomodulatory therapies increase the risk of cancer in patients with psoriasis?The British Journal of Dermatology
(Canadian Medical Association Journal) An updated guideline on screening for breast cancer emphasizes shared decision-making between women and their doctors, supporting women to make an informed decision based on personal preferences when the balance between benefits and harms is uncertain. The guideline, released by the Canadian Task Force on Preventive Health Care, is published in CMAJ (Canadian Medical Association Journal).
(Wiley) Researchers have uncovered an increased risk of cervical cancer in women whose cervical cells test positive for certain high-risk human papillomavirus (HPV) types but do not show any signs of cellular abnormalities. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help refine guidelines for cervical cancer screening.
ijl There have been many public health recommendations for avoiding UV radiation exposures. This is primarily due to concerns about skin cancer and especially melanoma, the most serious type of skin cancer. However, UV radiation is also known as the primary source of vitamin D and other compounds needed for good health. This brief commentary lists several of the many important recent studies of adverse health effects associated with low sun exposure, including some specific cancers, multiple sclerosis, diabetes, cardiovascular disease, autism, Alzheimer’s disease, and age-related macular degeneration. Our con...
ConclusionsUsing an often-quoted willingness-to-pay per QALY threshold in Australia (i.e. A$50,000), the treatment with nivolumab cannot be considered cost-effective. It might be funded publicly by special arrangements given unmet clinical needs for patients.
More News: Allergy & Immunology | Biochemistry | Biology | Bladder Cancer | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Epithelial Cancer | Genetics | Graduation | Health | Laboratory Medicine | Melanoma | Microbiology | Molecular Biology | Nanotechnology | Ovarian Cancer | Ovaries | Skin | Skin Cancer | Students | Study | Universities & Medical Training